Salvianolic Acid C is extracted from the root of Salvia miltiorrhiza, a perennial plant in the genus Salvia.

METHODS: Human periodontal stem cells hPDLSCs were pretreated with Salvianolic acid C (0-5 mM) for 1 h, then cultured with LPS (1 µg/mL) for 24 h. Cytokines were detected using ELISA kits.
RESULTS: Salvianolic acid C treatment significantly inhibited the expression of TNFα, IL-6 and IL-1β in a dose-dependent manner. [1]
METHODS: HEK293T cells stably expressing human-ACE2 were treated with Salvianolic acid C (0-100 µM), and viral entry was studied using the SARS-CoV-2 HSCs pseudovirus (PsV) system.
RESULTS: Salvianolic acid C inhibited SARS-CoV-2 PsV entry on 293T/ACE2 cells with an IC50 of 3.85 µM.[2]

METHODS: To investigate the effects on liver injury, Salvianolic acid C (5-20 mg/kg) was intraperitoneally injected into C57BL/6J mice with CCl4-induced hepatic fibrosis once a day for six days, followed by APAP (400 mg/kg) to induce liver injury.
RESULTS: Salvianolic acid C protects hepatocytes from APAP-induced injury by attenuating mitochondrial oxidative stress, inflammatory response, and cystatinase-mediated anti-apoptotic effects via inhibition of the Keap1/Nrf2/HO-1 signaling axis. [3]